News und Analysen
![New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized
Pfizer Inc. (NYSE:PFE) today announced detailed results of the first study to show the burden of both invasive and non-invasive Group B Streptococcus infections (GBS) among hospitalized adults in
![New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized
Pfizer Inc. (NYSE:PFE) today announced detailed results of the first study to show the burden of both invasive and non-invasive Group B Streptococcus infections (GBS) among hospitalized adults in
![Vaxxel Acquires Transgene's DuckCelt®-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Vaxxel Acquires Transgene's DuckCelt®-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses
Regulatory News:
Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s (Paris:TNG) proprietary DuckCelt®-T17 cell line.
![Savara to Report First Quarter 2020 Financial Results and Provide Business Update](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Savara to Report First Quarter 2020 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report first quarter 2020 financial results and provide a business update on Thursday, May 7, 2020
![Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will
![Illumina Reports Financial Results for First Quarter of Fiscal Year 2020](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Illumina Reports Financial Results for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.
First quarter 2020 results:
-
Revenue of $859 million, a 2% increase compared to
![Illumina Reports Financial Results for First Quarter of Fiscal Year 2020](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Illumina Reports Financial Results for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.
First quarter 2020 results:
-
Revenue of $859 million, a 2% increase compared to
![Illumina Reports Financial Results for First Quarter of Fiscal Year 2020](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Illumina Reports Financial Results for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2020.
First quarter 2020 results:
-
Revenue of $859 million, a 2% increase compared to
![Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Bixink Therapeutics, a new South Korean company working in the field of anti-cancer drugs and digital therapeutics, have
![NANOBIOTIX Announces First Quarter 2020 Revenues](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
NANOBIOTIX Announces First Quarter 2020 Revenues
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of
![Premier Inc. Data: As COVID-19 Cases Spike, Demand for Drugs Used to Treat Related, Co-Morbid Conditions Also Soars](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Premier Inc. Data: As COVID-19 Cases Spike, Demand for Drugs Used to Treat Related, Co-Morbid Conditions Also Soars
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today released new data finding that as COVID-19 cases peak, so does demand for drugs used to treat cardiovascular conditions
![Bayer – ein langfristiger Kaufkandidat: Börse ist Psychologie!](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Bayer – ein langfristiger Kaufkandidat: Börse ist Psychologie!
Noch vor einem Jahr war die Aktie von Bayer (WKN: BAY001) das große Thema unter den Anlegern. Grund hierfür waren immer neue Hiobsbotschaften im Zuge der Übernahme von Monsanto.
Denn eines der
![Bayer – ein langfristiger Kaufkandidat: Börse ist Psychologie!](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Bayer – ein langfristiger Kaufkandidat: Börse ist Psychologie!
Noch vor einem Jahr war die Aktie von Bayer (WKN: BAY001) das große Thema unter den Anlegern. Grund hierfür waren immer neue Hiobsbotschaften im Zuge der Übernahme von Monsanto.
Denn eines der
![Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Lantheus Holdings, Inc. Reports First Quarter 2020 Financial Results
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative
![Novocure Reports First Quarter 2020 Financial Results and Provides Company Update](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Novocure Reports First Quarter 2020 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2020, highlighting revenue growth and financial strength, clinical pipeline developments and the company’s
![Humana Foundation Commits $50M to Coronavirus Relief and Recovery Efforts](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Humana Foundation Commits $50M to Coronavirus Relief and Recovery Efforts
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), today announced it will deploy $50 million in immediate short-term and long-term relief and partner with national and community
![Quidel to Present Virtually at the BofA Securities 2020 Health Care Conference](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Quidel to Present Virtually at the BofA Securities 2020 Health Care Conference
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the
![Clovis Oncology to Present at the Bank of America Health Care Conference 2020](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clovis Oncology to Present at the Bank of America Health Care Conference 2020
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America Health Care Conference 2020 on Tuesday
![Spende von Illumina erweitert die Ressourcen des Africa Centre for Disease Control and Prevention für die auf Sequenzierung basierende COVID-19-Kontrolle](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Spende von Illumina erweitert die Ressourcen des Africa Centre for Disease Control and Prevention für die auf Sequenzierung basierende COVID-19-Kontrolle
Illumina, Inc. (NASDAQ: ILMN) freut sich, bekanntgeben zu dürfen, dass die Kommission der Afrikanischen Union im Namen des Africa Center for Disease Control and Prevention (CDC)
![Spende von Illumina erweitert die Ressourcen des Africa Centre for Disease Control and Prevention für die auf Sequenzierung basierende COVID-19-Kontrolle](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Spende von Illumina erweitert die Ressourcen des Africa Centre for Disease Control and Prevention für die auf Sequenzierung basierende COVID-19-Kontrolle
Illumina, Inc. (NASDAQ: ILMN) freut sich, bekanntgeben zu dürfen, dass die Kommission der Afrikanischen Union im Namen des Africa Center for Disease Control and Prevention (CDC)
![Spende von Illumina erweitert die Ressourcen des Africa Centre for Disease Control and Prevention für die auf Sequenzierung basierende COVID-19-Kontrolle](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Spende von Illumina erweitert die Ressourcen des Africa Centre for Disease Control and Prevention für die auf Sequenzierung basierende COVID-19-Kontrolle
Illumina, Inc. (NASDAQ: ILMN) freut sich, bekanntgeben zu dürfen, dass die Kommission der Afrikanischen Union im Namen des Africa Center for Disease Control and Prevention (CDC)
![LivaNova Reports First Quarter 2020 Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
LivaNova Reports First Quarter 2020 Results
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020.
For the first quarter of 2020, worldwide sales
![Lysogene Reports Its Cash Position as of 31 March 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Lysogene Reports Its Cash Position as of 31 March 2020
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today reports its cash position as of 31 March
![Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of the American Society of
![Dexcom Reports First Quarter 2020 Financial Results](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Dexcom Reports First Quarter 2020 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2020.
First Quarter 2020 and COVID-19 Pandemic Response Highlights:
-
Revenue grew 44%